Efficacy and safety of once-weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta-analysis.

ABSTRACT:

Aims

Once-weekly basal insulins may offer similar or superior HbA1c reduction compared to once-daily analogues in people with type 1 or type 2 diabetes. However, concerns about hypoglycaemia persist in individuals on multiple daily injections. This meta-analysis (PROSPERO CRD42024606874) aimed to evaluate the efficacy and safety of once-weekly basal insulin therapy in type 1 diabetes.

Materials and methods

A systematic search was conducted in MEDLINE, Web of Science and CENTRAL up to 1 April 2025. We included randomized controlled trials (RCTs) comparing insulin icodec or efsitora against once-daily basal insulins in people with type 1 diabetes. Three reviewers independently evaluated the retrieved citations. The primary outcome was the change in HbA1c. Meta-analysis was per

SUBMITTER: Di Gioia L 

PROVIDER: S-EPMC12673469 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature